Efanesoctocog Alfa Preventative Treatment for Hemophilia A with Joint Thickening
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests a new preventive treatment (efanesoctocog alfa) for people with hemophilia A who have joint lining thickening. The goal is to see if it helps protect joints.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate to severe hemophilia A (factor VIII levels at 5% or less).
- You are 12 years old or older.
- You have thickened joint lining (synovial hypertrophy) in at least one joint, confirmed by ultrasound.
- You have not had a major joint surgery in the last 3 months and don't have one planned soon.
- You have been using hemophilia preventive treatment (prophylaxis) for the past 12 months.
- You do not have a factor VIII inhibitor (a protein that blocks treatment) or other clotting disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two preventive treatments for severe hemophilia A—emicizumab versus factor VIII—to see how they affect joint and bone health. It may help you and others understand which option better protects joints and bones over the next several years.
This trial tests a new gene therapy called SPK-8011QQ for adults with severe or moderately severe hemophilia A. The goal is to see if a single infusion can help your body produce its own factor VIII, reducing or stopping the need for regular factor VIII injections.
This study tests how well a new factor VIII medicine, efanesoctocog alfa, protects your joints over time. It's for people with moderate or severe hemophilia A who are just starting this treatment.
This study checks how well efanesoctocog alfa (a preventive factor VIII treatment) protects your joints over time in people with hemophilia A. It involves regular checkups, joint assessments, and tracking of any bleeding episodes.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
This study watches how well damoctocog alfa pegol (a medicine to help blood clot) works in children with hemophilia A. It is for kids ages 7 to 12 who have used factor VIII before and do not have inhibitors (antibodies that stop the medicine from working).
Hear when a new Factor VIII Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.